VALBIOTIS SA (ALVAL.PA) Stock Price, Forecast & Analysis
Europe - Euronext Paris - EPA:ALVAL - FR0013254851 - Common Stock
ALVAL.PA Key Statistics, Chart & Performance
The current stock price of ALVAL.PA is 0.672 EUR. In the past month the price decreased by -8.7%. In the past year, price decreased by -51.65%.
ALVAL.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 68.02 | 44.18B | ||
| 1AE.DE | ARGENX SE | 68.21 | 44.30B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 18.82B | ||
| ABVX.PA | ABIVAX SA | N/A | 9.46B | ||
| 2X1.DE | ABIVAX SA | N/A | 9.31B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.84B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.84B | ||
| NANO.PA | NANOBIOTIX | N/A | 955.63M | ||
| 5CV.DE | CUREVAC NV | 6.1 | 796.20M | ||
| IVA.PA | INVENTIVA SA | N/A | 723.96M | ||
| PHIL.MI | PHILOGEN SPA | 20.53 | 684.22M | ||
| FYB.DE | FORMYCON AG | N/A | 439.10M |
Related stock screener links
About ALVAL.PA
Company Profile
Valbiotis SA engages in the products and candidate drugs designed to prevent metabolic diseases. The company is headquartered in Perigny, Nouvelle-Aquitaine and currently employs 44 full-time employees. The company went IPO on 2017-06-07. The firm specializes in developing nutrition solutions designed to prevent cardiometabolic diseases and provide nutritional support for patients. The company seeks to develop solutions designed to prevent type 2 diabetes, NASH, (non-alcoholic steatohepatitis) and obesity and to offer nutritional support. The firm prevents disease by developing products that reduce the risk factors of irreversible chronic diseases. The company provides patient support through new-generation medical nutrition solutions containing patented substances with clinically proven effects. Its products are plant-based and undergo strict scientific and clinical tests in collaboration with academic research centers.
Company Info
VALBIOTIS SA
12F rue Paul Vatine
Perigny NOUVELLE-AQUITAINE FR
Employees: 44
VALBIOTIS SA / ALVAL.PA FAQ
What does ALVAL do?
Valbiotis SA engages in the products and candidate drugs designed to prevent metabolic diseases. The company is headquartered in Perigny, Nouvelle-Aquitaine and currently employs 44 full-time employees. The company went IPO on 2017-06-07. The firm specializes in developing nutrition solutions designed to prevent cardiometabolic diseases and provide nutritional support for patients. The company seeks to develop solutions designed to prevent type 2 diabetes, NASH, (non-alcoholic steatohepatitis) and obesity and to offer nutritional support. The firm prevents disease by developing products that reduce the risk factors of irreversible chronic diseases. The company provides patient support through new-generation medical nutrition solutions containing patented substances with clinically proven effects. Its products are plant-based and undergo strict scientific and clinical tests in collaboration with academic research centers.
What is the current price of ALVAL stock?
The current stock price of ALVAL.PA is 0.672 EUR. The price increased by 2.28% in the last trading session.
Does ALVAL stock pay dividends?
ALVAL.PA does not pay a dividend.
What is the ChartMill technical and fundamental rating of ALVAL stock?
ALVAL.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about VALBIOTIS SA (ALVAL.PA) stock?
11 analysts have analysed ALVAL.PA and the average price target is 2.21 EUR. This implies a price increase of 228.87% is expected in the next year compared to the current price of 0.672.
Is VALBIOTIS SA (ALVAL.PA) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ALVAL.PA.
ALVAL.PA Technical Analysis
ALVAL.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALVAL.PA. ALVAL.PA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ALVAL.PA Financial Highlights
Over the last trailing twelve months ALVAL.PA reported a non-GAAP Earnings per Share(EPS) of -0.7. The EPS decreased by -7.69% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -55.55% | ||
| ROE | -92.58% | ||
| Debt/Equity | 0.24 |
ALVAL.PA Forecast & Estimates
11 analysts have analysed ALVAL.PA and the average price target is 2.21 EUR. This implies a price increase of 228.87% is expected in the next year compared to the current price of 0.672.
For the next year, analysts expect an EPS growth of 45.28% and a revenue growth 375% for ALVAL.PA